HRH2: IHC Expression in Cancer and Radioligand Target Profile
HRH2, histamine receptor H2, is a cell-surface protein (GPCR). In Human Protein Atlas immunohistochemistry, HRH2 staining is highest in colorectal cancer (33% of samples positive), ovarian cancer (9% of samples positive) and pancreatic cancer (8% of samples positive). Evidence on whether HRH2 internalizes is mixed. Clinical status: FDA-approved drug (any modality).
Is HRH2 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze HRH2 freeIs HRH2 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ⚠️ Tumor expression: Low IHC staining in colorectal cancer, 33% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
HRH2 IHC staining by cancer type
Protein expression of HRH2 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Colorectal Cancer | 0.15 | Low | 33% |
| Ovarian Cancer | 0.03 | Low | 9% |
| Pancreatic Cancer | 0.03 | Low | 8% |
Not detected by IHC in: skin cancer, head and neck cancer, lymphoma, breast cancer, melanoma, kidney cancer, thyroid cancer, bladder cancer, neuroendocrine tumors, cervical cancer, lung cancer, prostate cancer, gastric cancer, testicular cancer, endometrial cancer, glioma, liver cancer.
Is HRH2 internalized?
Uncertain. Insufficient literature found.
HRH2 clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for HRH2 yet. Search ClinicalTrials.gov for HRH2 trials.
HRH2 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See HRH2 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
HRH2 gene essentiality (DepMap)
CRISPR knockout effect across 1249 cancer cell lines: 0.11 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related colorectal cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · EGFR · FAP · CEA (CEACAM5) · EPCAM · SSTR2 · STEAP2
See all radioligand therapy targets in colorectal cancer.
See how HRH2 ranks against 15,000 targets for your indication.
Analyze HRH2 freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.